Mineralys’ Drug Significantly Cut Blood Pressure in Key Study

An experimental drug from Mineralys Therapeutics Inc. significantly lowered blood pressure in patients with treatment-resistant hypertension in a new study, though several stopped taking it because of side effects.

Patients taking the drug, called lorundrostat, saw their blood pressure fall twice as much as those given standard care in a key study needed to get US approval, according to the findings published Monday in JAMA. The medicine targets aldosterone, the main hormone that controls blood pressure.